About-cancer/treatment/clinical-trials/disease/melanoma/treatment

Chithandizo Chachipatala Kuyesedwa kwa Melanoma

Mayesero azachipatala ndi maphunziro ofufuza omwe amakhudza anthu. Mayeso azachipatala pamndandandawu ndi a chithandizo cha khansa ya khansa. Mayesero onse pamndandanda amathandizidwa ndi NCI.

Zambiri za NCI zokhudzana ndi mayesero azachipatala zimafotokozera mitundu ndi magawo am'mayesero ndi momwe amachitikira. Mayesero azachipatala amayang'ana njira zatsopano zotetezera, kuzindikira, kapena kuchiza matenda. Mungafune kuganizira zokhala ndi gawo pakuyesedwa kwachipatala. Lankhulani ndi dokotala wanu kuti akuthandizeni kusankha ngati mukuyenera.

Mayesero 1-25 a 260 1 2 3 ... 11 Kenako>

Therapy Target Yotsogozedwa ndi Kuyesedwa Kwachibadwa Pochiza Odwala Omwe Ali Ndi Matenda Olimba Otsitsimutsa, Lymphomas, kapena Multiple Myeloma (The MATCH Screening Trial)

Gawo ili lachiwiri la MATCH limafufuza momwe chithandizo chamankhwala chomwe chimayendetsedwa ndi kuyesa kwa majini chimagwira ntchito kwa odwala omwe ali ndi zotupa zolimba kapena ma lymphomas omwe apita patsogolo motsatira njira imodzi yothandizirana kapena yomwe palibe njira yovomerezeka yothandizira. Mayeso a chibadwa amayang'ana mitundu yapadera ya majini (majini) ya zotupa za odwala. Odwala omwe ali ndi vuto lachibadwa (monga kusintha kwa thupi, kukulitsa, kapena kusunthika) atha kupindula kwambiri ndi chithandizo chamankhwala chomwe chimayambitsa vuto la chibadwa chawo. Kuzindikira zovuta zamtunduwu poyamba kumatha kuthandiza madokotala kukonzekera chithandizo chokwanira kwa odwala omwe ali ndi zotupa zolimba, ma lymphomas, kapena angapo a myeloma.

Malo: malo 1189

Pembrolizumab pochiza odwala omwe ali ndi khansa yapakati III-IV yowopsa pachiwopsezo cha opaleshoni isanachitike kapena itatha

Gawo lachiwiri lachigawochi limafufuza momwe pembrolizumab imagwirira ntchito asanafike komanso pambuyo pochita opaleshoni pochiza odwala omwe ali ndi khansa ya melanoma yomwe ili pachiwopsezo chachitatu. Immunotherapy yokhala ndi ma monoclonal antibodies, monga pembrolizumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Kupatsa pembrolizumab isanachitike komanso pambuyo pochita opaleshoni kumatha kuthandizira bwino pochiza khansa ya khansa.

Malo: malo 709

Dabrafenib ndi Trametinib Yotsatira Ipilimumab ndi Nivolumab kapena Ipilimumab ndi Nivolumab Yotsatiridwa ndi Dabrafenib ndi Trametinib pochiza Odwala omwe ali ndi Gawo lachitatu-IV BRAFV600 Melanoma

Kafukufukuyu adafufuza momwe chithandizo choyambirira ndi ipilimumab ndi nivolumab chotsatiridwa ndi dabrafenib ndi trametinib chimagwira ndikuchifanizira ndi chithandizo choyambirira ndi dabrafenib ndi trametinib chotsatira ipilimumab ndi nivolumab pochiza odwala omwe ali ndi melanoma ya III-IV yomwe ili ndi kusintha komwe kumatchedwa BRAFV600 ndipo sichingachotsedwe ndi maopareshoni (osasinthika). Immunotherapy yokhala ndi ma monoclonal antibodies, monga ipilimumab ndi nivolumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Dabrafenib ndi trametinib zitha kulepheretsa kukula kwa chotupa poyang'ana mtundu wa BRAFV600.

Malo: malo 712

Ipilimumab yokhala ndi Nivolumab kapena yopanda pochiza odwala omwe ali ndi khansa yapakhungu yomwe ili gawo lachinayi kapena gawo lachitatu ndipo sangachotsedwe ndi maopareshoni

Gawo ili lachiwiri limawunika momwe ipilimumab yokhala ndi nivolumab imagwirira ntchito pochiza odwala khansa ya melanoma yomwe ndi gawo IV kapena gawo lachitatu ndipo sangathe kuchotsedwa ndi opaleshoni. Immunotherapy yokhala ndi ma monoclonal antibodies, monga ipilimumab ndi nivolumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira.

Malo: malo 600

Pembrolizumab pochiza odwala omwe ali ndi khansa ya khansa ya khansa ya m'mimba yomwe imatha kuchotsedwa ndi opaleshoni

Kuyeserera koyeserera uku kwa II kumafufuza momwe pembrolizumab imagwirira ntchito pochiza odwala omwe ali ndi desmoplastic melanoma (DM) yomwe imatha kuchotsedwa kapena kuchitidwa opaleshoni (yosasinthika). Ma antibodies a monoclonal, monga pembrolizumab, amatha kutseka mapuloteni ena omwe amalimbikitsa chitetezo chamthupi ndikuletsa kukula kwa chotupa.

Malo: malo 202

Basket Study ya Entrectinib (RXDX-101) yothandizira odwala omwe ali ndi zotupa zolimba zosunga NTRK 1/2/3 (Trk A / B / C), ROS1, kapena ALK Gene Rearrangements (Fusions)

Izi ndizotseguka, multicenter, Global Phase 2 basket basket ya entrectinib (RXDX-101) yochizira odwala omwe ali ndi zotupa zolimba zomwe zimakhala ndi NTRK1 / 2/3, ROS1, kapena ALK jini fusion. Odwala adzapatsidwa madengu osiyanasiyana kutengera mtundu wa chotupa ndi kuphatikiza kwa majini.

Malo: malo 26

Chitetezo ndi Kuchita Bwino kwa Pembrolizumab Poyerekeza ndi Placebo mu Resected High-Rage Stage II Melanoma (MK-3475-716 / KEYNOTE-716)

Kafukufukuyu azigwiritsa ntchito pembrolizumab (MK-3475) poyerekeza ndi placebo mwa omwe atenga nawo mbali pachipatala cha Stage II melanoma. Ophunzira nawo Gawo 1 alandila pembrolizumab kapena placebo mumapangidwe akhungu mpaka mizere 17. Ophunzira omwe amalandira placebo kapena omwe amasiya kulandira chithandizo atalandira ma pembrolizumab 17 mu Gawo 1, samayambiranso matenda mkati mwa miyezi isanu ndi umodzi atamaliza pembrolizumab mu Gawo 1, ndipo osayimitsa chithandizo ndi pembrolizumab yokhudzana ndi kubwereza matenda kapena kusalolera, atha kukhala oyenera landirani ma pembrolizumab owonjezera 35 mu Gawo 2 pamapangidwe otseguka. Lingaliro loyambirira la kafukufukuyu ndikuti pembrolizumab imakulitsa kupulumuka kosabwerezabwereza (RFS) poyerekeza ndi placebo.

Malo: 25 malo

Nivolumab wokhala ndi Ipilimumab kapena wopanda Pochiza Odwala Achichepere Omwe Amakhala Ndi Zotupa Zaposachedwa Kapena Zotsitsimula kapena Sarcomas

Gawo ili la mayesero a I / II limafufuza zoyipa ndi mankhwala abwino kwambiri a nivolumab akapatsidwa ndi kapena alibe ipilimumab kuti awone momwe amagwirira ntchito pochiza odwala achichepere kapena zotupa zolimba zomwe zabwerera (zabwereza) kapena osayankha chithandizo ( Zotsutsa). Immunotherapy yokhala ndi ma monoclonal antibodies, monga nivolumab ndi ipilimumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Sizikudziwika ngati nivolumab imagwira ntchito bwino payokha kapena ndi ipilimumab pochiza odwala omwe ali ndi zotupa zobwerezabwereza kapena zotsutsa kapena sarcomas.

Malo: 24 malo

Kukula kwa Mlingo ndi Kukula Kwa Magulu a NKTR-214 Kuphatikiza Ndi Nivolumab ndi Mankhwala Ena Oletsa Khansa kwa Odwala Omwe Ali Ndi Matenda Olimba Okhazikika (PIVOT-02)

Pakafukufukuyu wagawo zinayi, NKTR-214 iperekedwa limodzi ndi nivolumab mu Gawo 1, kuphatikiza nivolumab yokhala kapena yopanda chemotherapies zosiyanasiyana mu Part 2, komanso nivolumab ndi ipilimumab mu Gawo 3 & 4. Mu Gawo 1, a Akulimbikitsidwa Phase 2 Dose (RP2D) ya NKTR-214 kuphatikiza nivolumab idzatsimikizika. Mu Gawo 2, NKTR-214 yokhala ndi nivolumab ku RP2D idzayesedwa ngati mankhwala oyamba komanso / kapena ngati wachiwiri kapena wachitatu wa mankhwala osankha odwala omwe ali ndi Melanoma, Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC ), Urothelial Carcinoma (UC), Khansa ya m'mawere ya metastatic (mBC) ndi Colorectal Cancer (CRC). Kuphatikiza apo, mu Gawo 2, RP2D ya NKTR-214 yokhala ndi nivolumab ndi ma chemotherapies osiyanasiyana ndi ma regimen m'magulu osankhidwa a odwala a NSCLC atsimikizika. Mu Gawo 3, Mitundu ingapo yamitundu iwiri ya NKTR-214 kuphatikiza nivolumab ndi ipilimumab idzayesedwa posankha odwala omwe ali ndi RCC, NSCLC, Melanoma, ndi UC. Mu Gawo 4, chitetezo ndi magwiridwe antchito a maphatikidwe atatuwa adzayesedwanso posankha odwala omwe ali ndi RCC, NSCLC, Melanoma ndi UC.

Malo: malo 22

Gawo 1 / 1b Phunziro Lakuwunika Chitetezo ndi Kuleza Mtima kwa CPI-444 Nokha komanso Kuphatikiza ndi Atezolizumab mu Advanced Cancers

Ili ndi gawo lotseguka la 1 / 1b, multicenter, kusankha-kusankha kwa CPI-444, kamolekyu yaying'ono yamlomo yolunjika ku adenosine-A2A receptor pa T-lymphocyte ndi ma cell ena amthupi. Mlanduwu uphunzira za chitetezo, kulekerera, komanso ntchito zotsutsana ndi zotupa za CPI-444 ngati wothandizira m'modzi komanso kuphatikiza atezolizumab, PD-L1 inhibitor pamatumba osiyanasiyana olimba. CPI-444 imatseka adenosine kuti isamangidwe kupita ku cholandirira cha A2A. Adenosine amapondereza anti-chotupa ntchito ya ma T cell ndi ma cell ena amthupi.

Malo: malo 22

Kafukufuku wa Pembrolizumab (MK-3475) mwa Ophunzira a Ana omwe Ali ndi chotupa cha Advanced Solid kapena Lymphoma (MK-3475-051 / KEYNOTE-051)

Ili ndi kafukufuku wamagulu awiri wa pembrolizumab (MK-3475) mwa omwe akutenga nawo mbali ana omwe ali ndi mitundu ina ya khansa: - khansa yapakhungu yapitayi (miyezi 6 mpaka <wazaka 18), - atapitanso patsogolo, kubwerera m'mbuyo kapena kukonzanso imfa- ligand 1 (PD-L1) - chotupa cholimba chotupa kapena lymphoma (miyezi 6 mpaka <18 wazaka), - wobwereranso kapena wotsutsa wakale Hodgkin lymphoma (rrcHL) (zaka 3 mpaka <18 wazaka), kapena - patsogolo zotulukanso zolimba kapena zobwezeretsa microsatellite-instability-high (MSI-H) zolimba (miyezi 6 mpaka <zaka 18). Gawo 1 lipeza mlingo wololeza kwambiri (MTD) / maximum maximum dose (MAD), kutsimikizira mlingowo, ndikupeza gawo loyenera la Phase 2 (RP2D) la mankhwala a pembrolizumab. Gawo 2 liziwunikiranso za chitetezo ndi mphamvu kwa RP2D ya ana. Lingaliro loyambirira la kafukufukuyu ndikuti kulowetsa mtsempha (IV) wa pembrolizumab kwa ana omwe ali ndi khansa yapakhungu yapamwambayi; chotupa cholimba cha PD-L1 chotsogola, chobwereranso kapena chosokonekera kapena lymphoma ina; zotupa zotsogola, zobwereranso kapena zotsutsa za MSI-H; kapena rrcHL, zithandizira kuti muyeso wa Objective Response Rate (ORR) woposa 10% pamtundu umodzi wa khansa. Ndikusintha kwa 8, kulembetsa nawo omwe ali ndi zotupa zolimba komanso omwe atenga nawo gawo azaka zapakati pa 6 mpaka <zaka 12 ndi khansa ya khansa idatsekedwa. Kulembetsa ophunzira omwe ali ndi zaka ≥12 mpaka ≤18 zaka ndi khansa ya khansa ikupitilira. Kulembetsa nawo omwe ali ndi zotupa zolimba za MSI-H kukupitilizabe. kubwereranso kapena kutulutsa chotupa cha MSI-H cholimba; kapena rrcHL, zithandizira kuti muyeso wa Objective Response Rate (ORR) woposa 10% pamtundu umodzi wa khansa. Ndikusintha kwa 8, kulembetsa nawo omwe ali ndi zotupa zolimba komanso omwe atenga nawo gawo azaka zapakati pa 6 mpaka <zaka 12 ndi khansa ya khansa idatsekedwa. Kulembetsa ophunzira omwe ali ndi zaka ≥12 mpaka ≤18 zaka ndi khansa ya khansa ikupitilira. Kulembetsa nawo omwe ali ndi zotupa zolimba za MSI-H kukupitilizabe. kubwereranso kapena kutulutsa chotupa cha MSI-H cholimba; kapena rrcHL, zithandizira kuti muyeso wa Objective Response Rate (ORR) woposa 10% pamtundu umodzi wa khansa. Ndikusintha kwa 8, kulembetsa nawo omwe ali ndi zotupa zolimba komanso omwe atenga nawo gawo azaka zapakati pa 6 mpaka <zaka 12 ndi khansa ya khansa idatsekedwa. Kulembetsa ophunzira omwe ali ndi zaka ≥12 mpaka ≤18 zaka ndi khansa ya khansa ikupitilira. Kulembetsa nawo omwe ali ndi zotupa zolimba za MSI-H kukupitilizabe.

Malo: malo 19

Chitetezo ndi Kuchita Bwino kwa IMCgp100 Poyerekeza ndi Kafukufuku Wosankha mu Advanced Uveal Melanoma

Kuwunika kupulumuka kwa odwala achikulire a HLA-A * 0201 omwe ali ndi UM omwe sanalandire chithandizo akulandila IMCgp100 poyerekeza ndi Investigator's Choice ya dacarbazine, ipilimumab, kapena pembrolizumab.

Malo: malo 18

Enapotamab Vedotin (HuMax-AXL-ADC) Phunziro Lachitetezo mwa Odwala Omwe Ali Ndi Zotupa Zolimba

Cholinga cha mayeserowa ndi kudziwa kuchuluka kwa zomwe zimaloledwa ndikukhazikitsa chitetezo cha HuMax-AXL-ADC pakati pa odwala omwe ali ndi zotupa zolimba

Malo: malo 18

Phunziro la XmAb®20717 mu Ophunzira Omwe Ali Ndi Zotupa Zapamwamba Zolimba

Ili ndi gawo 1, kuchuluka kwa kuchuluka, kukwera kwa kuchuluka kwa kuchuluka kwa kuchuluka kwa MTD / RD ndi mtundu wa XmAb20717, kufotokoza chitetezo ndi kulolerana, kuyesa PK ndi immunogenicity, ndikuwunikiranso ntchito zotsutsana ndi zotupa za XmAb20717 m'mitu yomwe yasankhidwa zotupa zolimba zotsogola.

Malo: malo 15

Talimogene Laherparepvec ndi Pembrolizumab pochiza Odwala omwe ali ndi khansa ya Stage III-IV

Gawo ili lachiwiri limawunika momwe talimogene laherparepvec ndi pembrolizumab zimagwirira ntchito pochiza odwala omwe ali ndi khansa ya melanoma ya III-IV. Njira zochiritsira zachilengedwe, monga talimogene laherparepvec, zimagwiritsa ntchito zinthu zopangidwa kuchokera kuzinthu zamoyo zomwe zimatha kulimbikitsa kapena kupondereza chitetezo chamthupi m'njira zosiyanasiyana ndikuletsa maselo am'mimba kukula. Immunotherapy yokhala ndi ma monoclonal antibodies, monga pembrolizumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira. Kupatsa talimogene laherparepvec ndi pembrolizumab kumatha kugwira ntchito bwino pochiza odwala khansa ya khansa pochepetsa chotupacho.

Malo: Malo 16

Dabrafenib, Trametinib, ndi Navitoclax Pochiza Odwala omwe ali ndi BRAF Mutant Melanoma kapena Zotupa Zolimba Zomwe Zili Metastatic kapena Sizingachotsedwe ndi Opaleshoni

Gawo ili la mayesero a I / II limafufuza zoyipa ndi kuchuluka kwa dabrafenib, trametinib, ndi navitoclax ndikuwona momwe amagwirira ntchito pochiza odwala omwe ali ndi BRAF mutant melanoma kapena zotupa zolimba zomwe zafalikira mbali zina za thupi kapena sizingachotsedwe mwa opaleshoni. Dabrafenib, trametinib, ndi navitoclax zitha kuyimitsa kukula kwa ma cell a chotupa poletsa ma enzyme ena ofunikira kuti maselo akule.

Malo: 24 malo

Kafukufuku Wa Avelumab Ophatikizana Ndi Ma Cancer Ena Omwe Amadziteteza Ku Ma Malignancies Otsogola (JAVELIN Medley)

Izi ndi gawo la 1b / 2 la kukhathamiritsa kwa muyeso kuti muwone za chitetezo, pharmacokinetics, pharmacodynamics, ndi ntchito zoyambirira za antitumor za avelumab (MSB0010718C) kuphatikiza ma immunotherapies ena a khansa mwa odwala omwe ali ndi zotupa zakomweko kapena zotupa. Cholinga chachikulu ndikuwunika chitetezo ndi zisonyezo zoyambirira zogwira mtima zamagulu osiyanasiyana avelumab ndi ma immunotherapies ena a khansa, kukhathamiritsa ma dosing regimens ngati kuli koyenera, pazizindikiro zochepa.

Malo: malo 12

Kafukufuku Wofufuza za Immuno-Therapy Kafukufuku Wowunika Chitetezo, Kuleza Mtima ndi Kugwira Ntchito kwa Anti-LAG-3 Popanda Anti-PD-1 Pochiza Zotupa Zolimba

Cholinga cha phunziroli ndikuwunika chitetezo, kulekerera komanso kugwiritsa ntchito mankhwala oyesera BMS-986016 yoperekedwa yokha komanso kuphatikiza nivolumab mwa odwala omwe ali ndi zotupa zolimba zomwe zafalikira komanso / kapena zomwe sizingachotsedwe ndi opaleshoni. Mitundu yotsatira yotupa imaphatikizidwa mu kafukufukuyu: Non-Small Cell Lung Cancer (NSCLC), khansa yam'mimba, hepatocellular carcinoma, renal cell carcinoma, khansa ya chikhodzodzo, squamous cell carcinoma ya mutu ndi khosi, ndi khansa ya khansa, yomwe sinakhalepo kale amathandizidwa ndi immunotherapy. NSCLC ndi khansa ya khansa yomwe idalandirapo mankhwala a immunotherapy.

Malo: malo 12

Chitetezo, Kuleza Mtima ndi PK Phunziro la DCC-2618 mwa Odwala Okhala Ndi Zovuta Zapamwamba

Izi ndi gawo la 1, lotseguka, loyambirira-mwa-munthu (FIH) kuchuluka kwa kuchuluka kwa kuchuluka kwa mayeso opangidwa kuti athe kuyesa chitetezo, kulolerana, pharmacokinetics (PK), pharmacodynamics (PD) ndi zoyambirira antitumor zochitika za DCC-2618, zoyendetsedwa pakamwa (PO), mwa odwala achikulire omwe ali ndi vuto lowopsa. Kafukufukuyu ali ndi magawo awiri, gawo lokulitsa mlingo komanso gawo lokulitsa.

Malo: malo 12

Kafukufuku wa NKTR-214 Ophatikizidwa ndi Nivolumab vs Nivolumab Yokha mwa Omwe Atenga Nawo Pachimake Pakale Pomwe Sangathe Kugwiritsa Ntchito kapena Metastatic Melanoma

Cholinga cha phunziroli ndikuyesa kuyesera (momwe mankhwala amagwirira ntchito), chitetezo, ndi kulolerana kwa mankhwala ofufuza omwe amatchedwa NKTR-214, akaphatikizidwa ndi nivolumab motsutsana ndi nivolumab yoperekedwa yokha mwa omwe ali nawo omwe ali ndi khansa yapakhungu ya khansa ya khansa ya khansa yomwe mwina osakhoza kuchitidwa opaleshoni kapena kufalikira

Malo: malo 10

Phunziro la Relatlimab Plus Nivolumab Poyerekeza ndi Nivolumab Yokha mwa Ophunzira Ndi Advanced Melanoma

Cholinga cha phunziroli ndikuwona ngati nivolumab kuphatikiza ndi relatlimab ndiyothandiza kwambiri kuposa nivolumab yokha pochiza melanoma kapena melanoma yomwe singafalikire

Malo: malo 13

Pembrolizumab ndi Ipilimumab Pochiza Odwala Omwe Amadwala Kwambiri Melanoma

Gawo ili lachiwiri limawunika momwe pembrolizumab ndi ipilimumab zimagwirira ntchito pochiza odwala omwe anali ndi khansa yapakhungu yomwe idafalikira kumadera ena a thupi. Immunotherapy yokhala ndi ma monoclonal antibodies, monga pembrolizumab ndi ipilimumab, imatha kuthandizira chitetezo chamthupi kulimbana ndi khansa, ndipo imatha kusokoneza kuthekera kwa maselo otupa kukula ndikufalikira.

Malo: malo 10

Clinical Study of CMP-001 Kuphatikiza Ndi Pembrolizumab kapena ngati Monotherapy

Kafukufukuyu azachitika m'magulu awiri: Gawo 1 liziwongoleredwa pogwiritsa ntchito kapangidwe ka Dose Escalation ndi Kukula. Gawo la 1 Dose Escalation Phase ya kafukufukuyu liziwunika mlingo woyenera komanso wololera kuti uwunikidwenso mgawo la Kukula kwa Mlingo wa Gawo 1. Gawo 2 la phunziroli lidzachitika mofananamo ndi Gawo 1 Kukula Kwa Mlingo Wowonjezera ndipo liziwunika chitetezo ndi mphamvu ya CMP-001 ikaperekedwa ngati monotherapy.

Malo: malo 12

Phase 1b / 2 Kuyesedwa kwa Lenvatinib (E7080) Plus Pembrolizumab mu Mitu Yokhala Ndi Zotupa Zosankhidwa

This is an open-label Phase 1b / 2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 6 cohorts at the MTD from Phase 1b (lenvatinib 20 mg / day orally + pembrolizumab 200 mg Q3W, IV).

Location: 10 locations

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Kafukufuku wopitilira, wowerengera wowerengera wowunika wothandizila wa cell cell (ACT) kudzera kulowetsedwa kwa LN-144 (autologous TIL) ndikutsatiridwa ndi interleukin 2 (IL-2) pambuyo pa dongosolo la nonmyeloablative lymphodepletion (NMA LD).

Malo: malo 13

1 2 3 ... 11 Kenako>